83 related articles for article (PubMed ID: 19255894)
1. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain.
Fraternale A; Paoletti MF; Casabianca A; Orlandi C; Millo E; Balestra E; Damonte G; Perno CF; Magnani M
J Drug Target; 2009 May; 17(4):278-85. PubMed ID: 19255894
[TBL] [Abstract][Full Text] [Related]
2. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
3. Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication.
Pesce CD; Bolacchi F; Bongiovanni B; Cisotta F; Capozzi M; Diviacco S; Quadrifoglio F; Mango R; Novelli G; Mossa G; Esposito C; Ombres D; Rocchi G; Bergamini A
Antiviral Res; 2005 Apr; 66(1):13-22. PubMed ID: 15781127
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.
Lavigne C; Thierry AR
Biochem Biophys Res Commun; 1997 Aug; 237(3):566-71. PubMed ID: 9299405
[TBL] [Abstract][Full Text] [Related]
6. Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription.
Lee R; Kaushik N; Modak MJ; Vinayak R; Pandey VN
Biochemistry; 1998 Jan; 37(3):900-10. PubMed ID: 9454580
[TBL] [Abstract][Full Text] [Related]
7. Cellular delivery of peptide nucleic acid by cell-penetrating peptides.
Kilk K; Langel U
Methods Mol Biol; 2005; 298():131-41. PubMed ID: 16044544
[TBL] [Abstract][Full Text] [Related]
8. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
10. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
Rossi L; Franchetti P; Pierigé F; Cappellacci L; Serafini S; Balestra E; Perno CF; Grifantini M; Caliò R; Magnani M
J Antimicrob Chemother; 2007 Apr; 59(4):666-75. PubMed ID: 17327293
[TBL] [Abstract][Full Text] [Related]
12. Relative levels of inhibition of p24 gene expression by different 20-mer antisense oligonucleotide sequences targeting nucleotides + 1129 to + 1268 of the HIV-1 gag genome: an analysis of mechanism.
Anazodo MI; Duta E; Friesen AD; Wright JA
Biochem Biophys Res Commun; 1996 Dec; 229(1):305-9. PubMed ID: 8954123
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
14. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Schafer EA; Venkatachari NJ; Ayyavoo V
Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
Paulus C; Ludwig C; Wagner R
Virology; 2004 Dec; 330(1):271-83. PubMed ID: 15527852
[TBL] [Abstract][Full Text] [Related]
16. Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
Magnani M; Balestra E; Fraternale A; Aquaro S; Paiardini M; Cervasi B; Casabianca A; Garaci E; Perno CF
J Leukoc Biol; 2003 Nov; 74(5):764-71. PubMed ID: 12960277
[TBL] [Abstract][Full Text] [Related]
17. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs.
Konopka K; Düzgüneş N; Rossi J; Lee NS
J Drug Target; 1998; 5(4):247-59. PubMed ID: 9713975
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA).
Bendifallah N; Rasmussen FW; Zachar V; Ebbesen P; Nielsen PE; Koppelhus U
Bioconjug Chem; 2006; 17(3):750-8. PubMed ID: 16704214
[TBL] [Abstract][Full Text] [Related]
19. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
[TBL] [Abstract][Full Text] [Related]
20. Effect of limonin and nomilin on HIV-1 replication on infected human mononuclear cells.
Battinelli L; Mengoni F; Lichtner M; Mazzanti G; Saija A; Mastroianni CM; Vullo V
Planta Med; 2003 Oct; 69(10):910-3. PubMed ID: 14648393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
